Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J sales

This article was originally published in The Tan Sheet

Executive Summary

McNeil Consumer & Specialty Pharmaceuticals "will maintain a limited number of products containing pseudoephedrine for behind the counter sale" but "is in the process of reformulating our products that contain this ingredient," J&J VP- Investor Relations Helen Short stated during a third-quarter earnings call Oct. 18. The "negative impact" of restrictions implemented on products containing pseudoephedrine was responsible for offsetting sales growth for the McNeil division during the third quarter, Short added. The McNeil franchise had operational growth of 11% for the third quarter, six points of which were a result of a reclassification of certain OTC products from the pharmaceutical division to McNeil in January, Short said. Imodium, Pepcid and Motilium were among those reclassified (1"The Tan Sheet" July 25, 2005, p. 10). Global consumer sales of $2.2 bil. for the quarter represented an increase of 10.2% over the prior-year period, the firm said...

You may also be interested in...

McNeil Sales Still Slowed By Pseudoephedrine Limits

Pseudoephedrine restrictions were the primary driver behind a 7% decline in first-quarter U.S. sales for Johnson & Johnson's McNeil Consumer division, J&J reported during an April 18 earnings call

Perrigo’s Full Range Of Pseudoephedrine Stand-Ins Must Wait For Next Year

Perrigo will not have a complete phenylephrine portfolio available to replace pseudoephedrine products until next year's cough/cold season, the company said during a fiscal 2006 first-quarter earnings call

McNeil Product Reclassification Accounts For 50% International Sales Gain

McNeil's international OTC drug and nutritional sales rose 50% on a reported basis in the second quarter, reflecting the addition of a number of OTCs that were previously part of parent J&J's pharmaceutical group

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts